07:28 AM EDT, 08/20/2024 (MT Newswires) -- GSK (GSK) said on Tuesday that the US Food and Drug Administration granted breakthrough therapy designation to its experimental therapy, GSK5764227, to treat certain patients with extensive-stage small-cell lung cancer.

The breakthrough therapy designation speeds up the development and review of drugs or therapies that show promise in treating severe conditions.

Price: 41.36, Change: -0.16, Percent Change: -0.39